Background {#Sec1}
==========

Injectable beta-interferons (IFN-β) and glatiramer acetate (GA) are mainstays of first-line treatment for relapsing-remitting multiple sclerosis (RRMS), with the primary goals of reducing the rate of relapses and delaying disease progression. Newer therapies such as alemtuzumab yield greater effects in reducing relapse rate and slowing disease progression, and patients may prefer therapies such as dimethyl fumarate or teriflunomide because of their oral mode of administration. However, amongst other disease-modifying therapies (DMTs), IFN-β and GA both have well-established long-term safety profiles without the severe side effects presented by other drugs. While IFN-β and GA are not appropriate for aggressive forms of RRMS (i.e. highly active RRMS or rapidly evolving-severe RRMS), the Association of British Neurologists (ABN) classifies these as 'drugs of moderate efficacy' \[[@CR1]\]. Beginning in 2017, an appraisal committee of the UK National Institute for Health and Care Excellence received evidence as part of its reconsideration of the clinical and cost effectiveness of IFN-β and GA for use in the UK National Health Service. The work presented here, the full record of which can be found at \[[@CR2]\], draws from our report to this appraisal committee.

There are currently five licensed IFN-β drugs indicated for RRMS. These include: two IFN β-1a (Avonex® (Biogen, Cambridge, Massachusetts, USA), administered via intramuscular injection once weekly at a dose of 30 μg; and Rebif® (Merck, Darmstadt, Germany), administered via subcutaneous injection three times weekly at a dose of either 44 or 22 μg); one pegylated IFN β-1a (Plegridy® (Biogen, Cambridge, Massachusetts, USA), administered via subcutaneous injection every 2 weeks at a dose of 125 μg); and two equivalent IFN β-1b (Betaferon® (Bayer, Leverkusen, Germany) and Extavia® (Novartis, Bale, Switzerland), both administered via subcutaneous injection every other day at a dose of 250 μg). Moreover, there are two licensed formulations of GA (Copaxone® (Teva, Petah Tikva, Israel)), both administered via subcutaneous injection: one at a dose of 20 mg daily, and another at a dose of 40 mg three times weekly. The mechanisms by which either type of drug exerts its effects in patients with MS are not fully understood, but it is now thought that these drugs induce a broad immunomodulatory effect that modifies the immune processes responsible for the pathogenesis of MS.

Though several systematic reviews incorporating network meta-analyses (NMAs) have considered the comparative effectiveness of treatments for RRMS, these have considered doses that do not correspond to the marketing authorisation and thus are not relevant to clinical practice (Tramacere et al. \[[@CR3]\], Filippini et al. \[[@CR4]\]), excluded relevant doses within drugs' marketing authorisations (Tolley et al. \[[@CR5]\]), or included trials across differing severities of MS (Hadjigeorgiou et al. \[[@CR6]\]). Our goal in this systematic review and NMA is to provide an up-to-date and consistent summary of the comparative effectiveness of IFN-β and GA on annualised relapse rate (ARR), disability progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs' recommended dosages.

Methods {#Sec2}
=======

This systematic review was part of a larger evidence synthesis project considering the effectiveness of treatments for several types of MS. Our protocol is registered on PROSPERO as CRD42016043278. The methods and results described here draw on our closely related work for the UK National Institute for Health and Care Excellence, the full report of which was provided to the National Institute for Health Research \[[@CR2]\]. In the original protocol, we described that we would stratify comparisons by type of MS. Here, we report clinical effectiveness findings relating to RRMS specifically.

Searches {#Sec3}
--------

We identified and examined past relevant systematic reviews, conducted update searches in multiple databases, checked references of included studies, contacted experts in the field, and screened websites for relevant publications. We undertook the main database searches in January and February 2016. These update searches were limited by date to the beginning of 2012 (the year the searches were undertaken for the last comprehensive systematic review and NMA by Filippini et al. \[[@CR4]\]) onwards, although we included trials without regard to publication date. This review was chosen because of the breadth of its scope, search strategy and eligibility criteria. A full record of searches is provided in Additional file [1](#MOESM1){ref-type="media"}.

We included: a) randomised controlled trials published as full-text reports in English (as well as systematic reviews, or meta-analyses to enable reference checking), b) in people diagnosed with RRMS, c) where the intervention was one of the drugs used within indication at the recommended dosage according to the summary of product characteristics as authorised by the European Medicines Agency (EMA), and d) where the comparator was placebo or best supportive care without DMTs, or another of the interventions when used within indication. Included trials had patient populations primarily comprised of RRMS patients. Our primary outcomes were relapse frequency, disease progression, and discontinuation due to adverse events. Outcomes assessed were relapse rate, time to progression, or discontinuation due to adverse events as outcomes. Full exclusion criteria can be found in the review protocol.

Study selection {#Sec4}
---------------

First, two authors (XA and GJMT) independently examined relevant past systematic reviews (including Tramacere et al. \[[@CR3]\], Filippini et al. \[[@CR4]\], and Clerico et al. \[[@CR7]\]) for studies meeting the inclusion criteria. We verified inclusion of these studies by examining their full text. For updated and new searches, we collected all retrieved records in a specialised database and removed duplicate records. We pilot-tested a screening form based on the predefined study inclusion and exclusion criteria. Subsequently, two reviewers (XA and GJMT) applied the inclusion/exclusion criteria and screened all identified bibliographic records on title/abstract and then using full texts. Any disagreements over eligibility were resolved through consensus or by a third party reviewer (AC). Reasons for exclusion of full text papers were documented.

Appraisal and extraction {#Sec5}
------------------------

All primary studies were appraised using the Cochrane risk of bias assessment tool \[[@CR8]\]. For all included studies, the relevant data were extracted independently by two reviewers using a data extraction form informed by the Centre for Reviews and Dissemination \[[@CR9]\]. Extracted data were entered into summary evidence Tables. A sample data extraction form is available in Additional file [1](#MOESM1){ref-type="media"}. Uncertainty and/or any disagreements were cross-checked with recourse to a third reviewer where necessary and resolved by discussion.

Meta-analysis {#Sec6}
-------------

We undertook separate meta-analyses corresponding to each of our review outcomes. Data preparation methods to generate summary effect sizes for each study are detailed in Additional file [1](#MOESM1){ref-type="media"}.

First, for relapse frequency, we elected to meta-analyse rate ratios (RR) of relapses as an overall measure. This was the most commonly reported measure for relapse frequency. Where necessary, we converted arm-level data into rate ratios. Where studies presented different estimates for relapse frequency, we preferred estimates of protocol-defined, clinician-confirmed relapses over non-protocol-defined relapses or self-reported relapses.

Second, disease progression is frequently defined in clinical trials of DMTs in MS using the Expanded Disability Status Scale (EDSS), a scale which ranges from 0 to 10. While the EDSS is described as a disability scale (and thus, trials present this as disability progression), it is perhaps better understood as a scale measuring impairment and mobility. We used hazard ratios (HR) to examine differences between study arms in time to progression, where progression was confirmed at either 3 or 6 months after an initial signal (generally an increase in EDSS of 0.5 or 1.0 points). We separated estimates for progression confirmed at 3 months and confirmed at 6 months, as we could not establish whether measures were commensurate.

Third, we estimated models for discontinuation due to AEs, using risk ratios as a summary measure. We also estimated one model with studies closest to 24 months of follow-up. This was because risk ratios are time dependent and we could not reliably estimate person-years of follow-up in each arm across all studies to convert study-level estimates to rate ratios.

We pooled outcomes for each intervention-comparator contrast using random effects meta-analysis in Stata v14 and examined these pairwise meta-analyses for heterogeneity, measured as Cochran's Q and I^2^. Subsequently, we used the package -network- \[[@CR10]\] in Stata v14 to estimate network meta-analyses. We used a common heterogeneity model, where the between-studies variance is assumed equal across comparisons. After estimating a consistency model (i.e. where direct evidence for a contrast between two treatments is assumed to agree with indirect evidence for that contrast), we checked for inconsistency using an omnibus Wald test from a design-by-treatment interaction model and the side-splitting method to test for differences in the effectiveness estimates between direct and indirect evidence. Where evidence of inconsistency existed, we considered the direction of inconsistency. We also assessed transitivity conceptually by examining networks of evidence for imbalance of trial-level effect modifiers (e.g. sex, age and duration of MS diagnosis; date of trial publication), though we did not have enough studies on each comparison to undertake network meta-regression.

Lastly, we used a bootstrapping method to resample from our estimates of intervention effectiveness and develop probabilities of each treatment's relative position to the others. We then used the surface under the cumulative ranking curve (SUCRA) to produce a unified ranking of treatments.

Publication bias {#Sec7}
----------------

We aimed to use funnel plots to examine studies for the presence of asymmetry, possibly due to publication bias, other reporting biases, heterogeneity or methodological inadequacies in included studies, in pairwise comparisons where there were more than 10 studies for an intervention-comparator contrast.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

We identified 6420 potentially relevant records. We removed 6146 records which did not meet our inclusion criteria at title/abstract stage, leaving 274 records to be examined at full-text. Among these, we excluded 232, leading to 42 publications meeting our inclusion criteria and corresponding to 24 primary studies. Study selection is summarised in Fig. [1](#Fig1){ref-type="fig"}. Additional studies related to other MS phenotypes and are described in the full report of our work for the National Institute for Health and Care Excellence \[[@CR2]\].Fig. 1PRISMA flowchart

Excluded studies {#Sec10}
----------------

We excluded two trials in relevant populations and interventions because they did not present relevant outcomes (Schwartz 1997 \[[@CR11]\]) or did not present outcomes in a form suitable for meta-analysis (Mokhber 2014 \[[@CR12]\]). We also excluded one small trial with a mixed RRMS/SPMS population (REMAIN 2012 \[[@CR13]\], RRMS *n* = 13) as treatment switching was explicitly allowed and data were not stratified by type of MS. Breakdown of studies by exclusion criterion is summarised in Additional file [2](#MOESM2){ref-type="media"}.

Included studies {#Sec11}
----------------

We included 24 trials published between 1987 and 2015. Included studies are detailed in Table [1](#Tab1){ref-type="table"}. In total, 14 trials were placebo-controlled, of which three (BRAVO 2014 \[[@CR14]\], CONFIRM 2012 \[[@CR15]\] and Kappos 2011 \[[@CR16]\]) principally aimed to test the effectiveness of a new agent against either IFN-β or GA alongside a placebo control. The remaining 10 trials only compared active drugs against each other. One trial (AVANTAGE 2014 \[[@CR17]\]) reported only adverse events data. The modal follow-up was 24 months.Table 1Characteristics of included studiesStudy ID\
MS type (diagnostic criteria)Study detailsCharacteristics of participants at baselineInterventionParticipantsADVANCE 2014\
RRMS (2005 McDonald criteria)Country: USA, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Estonia, France, Georgia, Germany, Greece, India, Latvia, Mexico, Netherlands, New Zealand, Peru, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United Kingdom.\
No. of countries: 26\
Centres: 183\
Study period: June 2009 and November 2011.\
Sponsor: Biogen IdecMean age: 36.5 (9.9)\
Mean sex: 71% female\
Race: 82% white\
EDSS Score: 2.5\
Relapse rate: 1.6 within the previous 12 months, 2.6 within the previous 36 months\
Time from diagnosis of MS: 3.6 years\
Other clinical features of MS: Time from first MS symptoms: 6.6 yearsArm 1: pegylated IFN β-1a 125 μg SC every 2 weeks (Plegridy)\
Arm 2: PlaceboRandomised\
512 arm 1\
500 arm 2AVANTAGE 2014\
RRMS/CIS, diagnostic criteria unclearCountry: France\
No. of countries: 1\
Centres: 61\
Study period: March 2006--April 2008, 3 months follow up\
Sponsor: BayerMean age: 38.7\
Mean sex: 75% female\
Race: NA\
EDSS Score: *1.8 ± 1.3*\
Mean number of relapse rate: 2.1 ± 1.1\
Time from diagnosis of MS: 3.3 (6.4) years\
Other clinical features of MS: NAArm 1: IFN β-1b 250 μg SC every other day (Betaferon) via Betaject\
Arm 2: IFN β-1b 250 μg SC every other day (Betaferon) via Betaject light\
Arm 3: IFN β-1a 44 SC three times weekly (Rebif) via Rebiject IIIncluded:\
73 arm 1\
79 arm 2\
68 arm 3BECOME 2009\
RRMS/CIS (likely McDonald 2001 or 2005)Country: USA\
No. of countries: 1\
Centres: 2\
Study period: Not specified, follow up over 2 years\
Sponsor: Bayer Schering pharmaMean age: 36\
Mean sex: 69% females\
Race: 52% white\
Median EDSS Score: *2*\
Relapse rate: 1.8 and 1.9 ARR\
Time from diagnosis of MS: between 0.9 and 1.2\
Other clinical features of MS: 81% RRMS, 19% CIS; MSFC median 0.13Arm 1: IFN β-1b 250 μg SC every other day (Betaferon)\
Arm 2: GA 20 mg SC daily (Copaxone)Randomised\
36 arm 1\
39 arm 2BEYOND 2009\
RRMS (McDonald 2005)Country: Not specified\
No. of countries: 26\
Centres: 198\
Study period: November, 2003, and June, 2005. Follow up between 2 and 3.5 years\
Sponsor: BayerMean age 35.6\
Mean sex: 69.4% female\
Race: 91.9% white\
EDSS Score: 2.33\
Relapse rate: 1.6 relapses in last year\
Time from diagnosis of MS: 5.2 years\
Other clinical features of MS:\
3.6 relapses previously; 70.6% had two or more relapses in past 2 yearsArm 1: IFN β-1b 250 μg SC every other day (Betaferon)\
Arm 2: GA 20 mg SC daily (Copaxone)Randomised\
897 arm 1\
448 arm 2Bornstein 1987\
RRMS (Poser)Country: USA\
No. of countries: 1\
Centres: Not specified\
Study period: Not specified, follow up over 2 years\
Sponsor: public (grant from the National Institute of Neurological and Communicative Disorders and Stroke and grant from the National Institutes of Health)Mean age: 30.5\
Mean sex: 42% male/58% female\
Race: 96% white\
EDSS Score: *3.11*\
Relapse rate: 3.85 over 2 years\
Time from diagnosis of MS: 5.5 years duration of disease\
Other clinical features of MS: NAArm 1: GA 20 mg SC daily (Copaxone)\
Arm 2: PlaceboRandomised\
25 arm 1\
25 arm 2BRAVO 2014\
RRMS (McDonald 2005)Country: US, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Israel, Italy, Lithuania, Macedonia, Poland, Romania, Russia, Slovakia, South Africa, Spain, Ukraine and others not specified\
No. of countries: 18\
Centres: 140\
Study period: April 2008 to June 2011. 24 months follow up\
Sponsor: Teva Pharmaceutical IndustriesMean age: Median: 37.5 placebo, 38.5 IFN\
Mean sex: 71.3% females in placebo arm, 68.7% females in IFN arm\
Race: N/A\
EDSS Score: Median: 2.5 placebo, 2.5 IFN\
Median Relapse rate: previous year: 1.0 placebo, 1.0 IFN;\
previous 2 years: 2.0 placebo, 2.0 IFN\
Median Time from diagnosis of MS: 1.2 placebo, 1.4 IFN\
Other clinical features of MS: NAArm 1: IFN β-1a 30 μg IM once weekly (Avonex)\
Arm 2: Oral placebo once-daily with neurologist monitoringRandomised\
447 arm 1\
450 arm 2Calabrese 2012\
RRMS (McDonald 2005)Country: Italy\
No. of countries: 1\
Centres: 1\
Study period: 1 Jan 2007--30 June 2008\
Follow up over 2 years\
Sponsor: grant from Merck Serono S.AMean age: 36.5 (9.9)\
Mean sex: 70.2% of female/20.8% of male\
Race: NA\
EDSS Score: 2.1 (1.1)\
Relapse rate: 1.2 (0.7)\
Time from diagnosis of MS: 5.6 years (2.4)\
Other clinical features of MS: NoneArm 1: IFN β-1a 44 SC three times weekly (Rebif)\
Arm 2: IFN β-1a 30 μg IM once weekly (Avonex)\
Arm 3: GA 20 mg SC daily (Copaxone)Randomised\
55 arm 1\
55 arm 2\
55 arm 3CombiRx 2013\
RRMS (McDonald 2001, Poser)Country: United States, Canada\
No. of countries: 2\
Centres: 68\
Study period: January 2005--April 2012. Minimally 36 months follow up\
Sponsor: NIH, with materials provided by Biogen and TevaMean age 38.3\
Mean sex: 70.3% female\
Race: 87.6% white\
EDSS Score: 2.0\
Relapse rate: 1.7 relapses in last year, on average\
Time from diagnosis of MS: 1.2\
Other clinical features of MS:\
NAArm 1: IFN β-1a 30 μg IM once weekly (Avonex)\
Arm 2: GA 20 mg SC daily (Copaxone)Randomised\
250 arm 1\
259 arm 2CONFIRM 2012\
RRMS (McDonald 2005)Country: USA, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Estonia, France, Germany, Greece, India, Ireland, Israel, Latvia, Macedonia, Mexico, Republic of Moldova, New Zealand, Poland, Puerto Rico, Romania, Serbia, Slovakia, Spain, Ukraine\
No. of countries: 28\
Centres: 200\
Study period: 2 year follow up\
Sponsor: Biogen idecMean age 36.8\
Mean sex: 70% female\
Race: 84% white\
EDSS Score: 2.6\
Relapse rate: 1.4 in prior 12 months\
Time from diagnosis of MS: 4.6 years\
Other clinical features of MS:\
any prior DMTs (%) = 29%Arm 1: GA 20 mg SC daily (Copaxone)\
Arm 2: 2 placebo capsules orally thrice dailyRandomised\
360 arm 1\
363 arm 2Cop1 MSSG 1995\
RRMS (Poser)Country: USA\
No. of countries: 1\
Centres: 11\
Study period: October, 1991, and May, 1992. 2 year follow up.\
Sponsor: the FDA orphan drug program, the National multiple sclerosis society, and TEVA pharmaceuticalMean age 34.4.\
Mean sex: 73% female\
Race: 94% white\
EDSS Score: 2.6\
Relapse rate: 2.9 prior 2-year rate\
MS duration:6.9 years\
Other clinical features of MS:\
ambulation index = 1.1Arm 1: GA 20 mg SC daily (Copaxone)\
Arm 2: PlaceboRandomised\
125 arm 1\
126 arm 2ECGASG 2001\
RRMS (Poser)Country: Canada\
No. of countries: 7\
Centres: 29\
Study period: Enrollment started in February 1997 and concluded in November 1997. 9 month follow up\
Sponsor: Teva Pharmaceutical IndustriesMean age 34\
Mean sex: NA\
Race: NA\
EDSS Score: 2.4\
Relapse rate: 2.65\
Disease duration (years): 8.1\
Other clinical features of MS:\
ambulation index = 1.15Arm 1: GA 20 mg SC daily (Copaxone)\
Arm 2: Placebo SC injectionsRandomised\
119 arm 1\
120 arm 2Etemadifar 2006\
RRMS (Poser)Country: Iran\
No. of countries: 1\
Centres: 1\
Study period: September 2002 and September 2004. 24 month follow up\
Sponsor: Not specifiedMean age 28.5\
Mean sex: 76% female\
Race: NA\
EDSS Score: 2.0\
Relapse rate 1 year prior: 2.2\
Time from diagnosis of MS: 3.2 years\
Other clinical features of MS: NoneArm 1: IFN β-1b 250 μg SC every other day (Betaferon)\
Arm 2: IFN β-1a 30 μg IM once weekly (Avonex)\
Arm 3: IFN β-1a 44 SC three times weekly (Rebif)Randomised\
30 arm 1\
30 arm 2\
30 arm 3EVIDENCE 2007\
RRMS (Poser)Country: USA, France, UK, Norway, Austria, Germany, France, Finland, Sweden, Canada\
No. of countries: 10\
Centres: 56\
Study period: Unclear. Minimally 48 weeks follow up, average 64.2\
Sponsor: SeronoMean age 37.9\
Mean sex: 74.8% female\
Race: 91.0% Caucasian\
EDSS Score: 2.3\
Median: 2.0\
Relapse rate: 2.6 Median 2.0 relapses in last 2 years\
Duration of MS: 6.6. Median: 4.0--4.1 years\
Other clinical features of MS:\
Time since last relapse (months): Median 3.9 to 4.4; mean 5.1Arm 1: IFN β-1a 44 SC three times weekly (Rebif)\
Arm 2: IFN β-1a 30 μg IM once weekly (Avonex)Randomised\
339 arm 1\
338 arm 2GALA 2013\
RRMS (McDonald 2005)Country: United States, Bulgaria, Croatia, Germany, Poland, Romania, and Ukraine and others\
No. of countries: 17\
Centres: 142\
Study period: Not specified. 12 months follow up.\
Sponsor: TEVA pharmaceutical industriesMean age 37.6\
Mean sex: 68% female\
Race: 98% Caucasian\
EDSS Score: 2.7\
Relapse rate: 1.3 in the prior 12 months, 1.9 in the prior 24 months\
Time from diagnosis of MS: NA\
Other clinical features of MS:\
Time from onset of first symptoms of MS = 7.7 yearsArm 1: GA 40 mg SC three times weekly (Copaxone)\
Arm 2: SC placebo injectionsRandomised\
943 arm 1\
461 arm 2GATE 2015\
RRMS (McDonald 2010)Country: USA, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Republic of Moldova, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom\
No. of countries: 20\
Centres: 118\
Study period: Recruited between December 7, 2011, and March 21, 2013; last follow-up December 2, 2013. Follow up 9 months (double-blind follow-up) + additional 15 months (open-label)\
Sponsor: Synthon BVMean age 33.1\
Mean sex: 66.4% female\
Race: NA\
EDSS Score: 2.7\
Relapse rate: 1.9 in prior 2 years\
Time from diagnosis of MS: NA\
Other clinical features of MS:\
• Time to onset of first symptoms to randomisation (years): 5.9\
• No history of prior disease treatment: 16.1%Arm 1: GA 20 mg SC daily (Copaxone)\
Arm 2: PlaceboRandomised\
357 arm 1\
84 arm 2IFNB MSSG 1995\
RRMS (Poser)Country: USA and Canada\
No. of countries: 2\
Centres: 11\
Study period: after 2 years of follow-up, all subjects were given the option of continuing treatment in a double-blind fashion, extending the total treatment period to 5.5 years for some patients\
Sponsor: Triton Biosciences, Berlex LaboratoriesMean age 35.6\
Mean sex: 70% female\
Race: 94% white\
EDSS Score: 2.9\
Relapse rate: 3.5 in prior 2 years\
Time from diagnosis of MS:4.3 years\
Other clinical features of MS:\
Baseline Scripps neurological rating scale: 80.8Arm 1: IFN β-1b 250 μg SC every other day (Betaferon)\
Arm 2: SC injections placeboRandomised\
124 arm 1\
123 arm 2IMPROVE 2012\
RRMS (McDonald 2005)Country: Italy, Germany, Serbia, Canada, Bulgaria, Estonia, Lithuania, Romania, Russia, Spain\
No. of countries: 10\
Centres: 5\
Study period: December 2006 to February 2009.\
Follow up 16 weeks for the double-blind phase, then 24 weeks where all patients received interferon beta 1-a, at last 4 weeks of safety period observation\
Sponsor: Merck Serono S.A.Mean age NA\
Mean sex: NA\
Race: NA\
EDSS Score: NA\
Relapse rate: NA\
Time from diagnosis of MS: NA\
Other clinical features of MS: NAArm 1: IFN β-1a 44 SC three times weekly (Rebif)\
Arm 2: SC injections of placeboRandomised\
120 arm 1\
60 arm 2INCOMIN 2002\
RRMS (Poser)Country: Italy\
No. of countries: 1\
Centres: 15\
Study period: October, 1997, and June, 1999. 2 year follow up\
Sponsor: Istituto Superiore di Sanita' of the Italian Ministry of Health and the Italian MS SocietyMean age 36.9\
Mean sex: 65% female\
Race: NA\
EDSS Score: 1.97\
Relapse rate 2 years prior: 1.45\
Time from diagnosis of MS: 6.3 years\
Other clinical features of MS: NoneArm 1: IFN β-1b 250 μg SC every other day (Betaferon)\
Arm 2: IFN β-1a 30 μg IM once weekly (Avonex)Randomised\
92 arm 1\
96 arm 2Kappos 2011\
RRMS (McDonald 2001)Country: Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Italy, Mexico, Romania, Russian Federation, Serbia, Slovakia, Spain, Switzerland, Ukraine, United Kingdom, USA and others\
No. of countries: 20\
Centres: 79\
Study period: Not specified. Up to 96 weeks follow up.\
Sponsor: F Hoffmann-La Roche Ltd., Biogen Idec IncMean age 37.5\
Mean sex: 65% female\
Race: 96% white\
EDSS Score: 3.3\
Relapse rate: NA\
Time from diagnosis of MS: median only\
Other clinical features of MS: NAArm 1: IFN β-1a 30 μg IM once weekly (Avonex)\
Arm 2: placebo injection every other weekRandomised\
55 arm 1\
54 arm 2Knobler 1993\
RRMS (Poser)Country: USA\
No. of countries: 1\
Centres: 3\
Study period: June and October 1986. Follow up 3 years (24 weeks of initial follow-up for the 5 groups then all the patients that had received 0.8 mU, 4MU and 16MU for 24 weeks received a dose of 8MU from week 24 to 3 years)\
Sponsor: Triton Biosciences, Inc. and Berlex Laboratories, IncMean age 35.6\
Mean sex: 48% female\
Race: NA\
EDSS Score: 3.1\
Mean exacerbation in prior 2 years: 2.84\
Time from diagnosis of MS: 6.6 years\
Other clinical features of MS:\
mean Scripps Neurological Rating Scale (NRS): 76.6Arm 1: IFN β-1b 250 μg SC every other day (Betaferon)\
Arm 2: Subcutaneous injection of placebo (1 mL like Betaseron 8 MU)Randomised\
6 arm 1\
7 arm 2MSCRG 1996\
RRMS (Poser)Country: USA\
No. of countries: 1\
Centres: 4\
Study period: November, 1990 to early 1993\
2 years follow up for all-patients + 2 additional years for patients completing dosing before the end of the first period of follow-up.\
Sponsor: National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS) grant R01--26321 and Biogen, Inc.Mean age 36.8\
Mean sex: 73.7% female\
Race: 93% white\
EDSS Score: *2.4*\
Relapse rate: 1.2\
MS duration (years): 6.5\
Other clinical features of MS: NoneArm 1: IFN β-1a 30 μg IM once weekly (Avonex)\
Arm 2: PlaceboRandomised\
158 arm 1\
143 arm 2PRISMS 1998\
RRMS (Poser)Country: Australia, Belgium, Canada, Finland, Germany, Netherlands, Sweden, Switzerland, UK\
No. of countries: 9\
Centres: 22\
Study period: May 1994 to February 1995 with 2 years follow up.\
Sponsor: Ares- SeronoMean age Median: 34.9\
Mean sex: 69% female\
Race: NA\
EDSS Score: 2.5 (SD 1.2)\
Relapse rate: 3.0 (SD 1.2)\
Time from diagnosis of MS: Median: 5.3 years)\
Other clinical features of MS: NAArm 1: IFN β-1a 22 μg SC three times weekly (Rebif)\
Arm 2: IFN β-1a 44 SC three times weekly (Rebif)\
Arm 3: PlaceboRandomised\
189 arm 1\
184 arm 2\
187 arm 3REFORMS 2012\
RRMS (McDonald 2005, Poser)Country: USA\
No. of countries: 1\
Centres: 27\
Study period: December 2006--November 2007. 12 weeks follow up\
Sponsor: EMD Serono, PfizerMean age 40.52 (SD 9.65)\
Mean sex: 70% female\
Race: 87.6% white\
EDSS Score: NA\
Relapse rate: 1.33 (SD 0.49) (of those with relapses)\
Time from diagnosis of MS: 1.47 yrs. (3.31)\
Other clinical features of MS:\
Percentage with no relapse in last 12 months: 24 (18.6%)\
Time since onset: 5.12 yrs. (6.68)\
Percentage diagnosed with Poser criteria: 36 (27.9%)\
Time since last relapse, of those with last-year relapses: 3.76 mos (2.93)\
Steroid treatment episodes: 0.50 (0.55)\
Percentage needing more than one course of steroids: 49 (38.0%)Arm 1: IFN β-1a 44 SC three times weekly (Rebif)\
Arm 2: IFN β-1b 250 μg SC every other day (Betaferon)Randomised\
65 arm 1\
64 arm 2REGARD 2008\
RRMS (McDonald 2001)Country: Argentina, Austria, Brazil, Canada, France, Germany, Ireland, Italy, Netherlands, Russia, Spain, Switzerland, UK, and USA\
No. of countries: 14\
Centres: 80\
Study period: February and December 2004, with 96 weeks follow up\
Sponsor: EMD Serono, PfizerMean age 36.8\
Mean sex: 29.5% male\
Race: 93.6% white\
EDSS Score: 2.34\
Relapse rate: Presented as distribution of relapses; months since last relapse about 5 on average\
Time from diagnosis of MS: Years since first relapse: 6.2\
Other clinical features of MS:\
Receiving steroid treatment in last 6 months: 43.7%Arm 1: IFN β-1a 44 SC three times weekly (Rebif)\
Arm 2: GA 20 mg SC daily (Copaxone)Randomised\
386 arm 1\
378 arm 2*RRMS* relapsing remitting MS, *SPMS* secondary progressive MS, *CIS* clinically isolated syndrome, *IFN* interferon, *GA* glatiramer acetate, *IM* intramuscular, *SC* subcutaneous, *NA* not available, *EDSS* Expanded Disability Status Score

Risk of bias {#Sec12}
------------

Risk of bias assessments are detailed in Table [2](#Tab2){ref-type="table"}. All studies that adequately detailed their method of randomisation (*n* = 15, 63%) were appraised as being at low risk of bias in this domain. A similar number of studies (*n* = 15) were judged to be at low risk of bias from allocation concealment, though one study (Bornstein 1987 \[[@CR18]\]) was classed as at high risk of bias in this domain. We judged that most studies were at high risk of bias in blinding of participants and personnel (*n* = 24, 83%) and blinding of outcome assessment (*n* = 18, 75%) due to a combination of injection site reactions in placebo-controlled trials and an open label design. Five studies (21%) were at high risk of bias from incomplete outcome data due to differential attrition between arms, and we believed that four studies (17%) were at high risk of bias from selective reporting. Finally, most studies (*n* = 17, 71%) were at high risk of bias from other sources, generally stemming from industry sponsorship.Table 2Risk of bias judgments for included studiesReferenceRandom sequence generationAllocation concealmentBlinding of participants and personnelBlinding of outcome assessmentIncomplete outcome dataSelective reportingOther sources of biasADVANCE 2014Low riskLow riskHigh riskHigh riskHigh riskLow riskHigh riskAVANTAGE 2014Unclear riskUnclear riskHigh riskHigh riskUnclear riskLow riskLow riskBECOME 2009Unclear riskUnclear riskHigh riskHigh riskLow riskLow riskHigh riskBEYOND 2009Low riskLow riskHigh riskHigh riskUnclear riskLow riskHigh riskBornstein 1987Unclear riskHigh riskHigh riskHigh riskLow riskLow riskLow riskBRAVO 2014Low riskLow riskHigh riskLow riskLow riskHigh riskHigh riskCalabrese 2012Low riskLow riskHigh riskHigh riskLow riskHigh riskLow riskCombiRx 2013Low riskLow riskLow riskLow riskHigh riskLow riskLow riskCONFIRM 2012Low riskLow riskHigh riskHigh riskHigh riskLow riskHigh riskCop1 MSSG 1995Unclear riskLow riskHigh riskHigh riskLow riskLow riskLow riskECGASG 2001Low riskLow riskHigh riskHigh riskLow riskUnclear riskHigh riskEtemadifar 2006Unclear riskUnclear riskHigh riskHigh riskLow riskUnclear riskUnclear riskEVIDENCE 2007Low riskLow riskHigh riskHigh riskLow riskLow riskHigh riskGALA 2013Unclear riskLow riskHigh riskHigh riskUnclear riskLow riskHigh riskGATE 2015Low riskLow riskHigh riskHigh riskLow riskLow riskHigh riskIFNB MSSG 1995Unclear riskUnclear riskHigh riskHigh riskHigh riskLow riskHigh riskIMPROVE 2012Unclear riskLow riskUnclear riskUnclear riskUnclear riskHigh riskHigh riskINCOMIN 2002Low riskLow riskHigh riskHigh riskLow riskLow riskLow riskKappos 2011Low riskLow riskHigh riskHigh riskLow riskHigh riskHigh riskKnobler 1993Unclear riskUnclear riskHigh riskHigh riskUnclear riskUnclear riskHigh riskMSCRG 1996Low riskUnclear riskLow riskLow riskHigh riskUnclear riskHigh riskPRISMS 1998Low riskLow riskUnclear riskLow riskLow riskLow riskHigh riskREFORMS 2012Low riskUnclear riskHigh riskHigh riskUnclear riskLow riskHigh riskREGARD 2008Low riskUnclear riskHigh riskLow riskLow riskLow riskHigh risk

Annualised relapse rates {#Sec13}
------------------------

Direct evidence from comparisons is shown in Fig. [2](#Fig2){ref-type="fig"}. All drugs had a beneficial effect on ARR as compared to placebo. None of the pooled comparisons showed evidence of a statistically significant effect favouring one drug over another drug. Heterogeneity quantified by I^2^ ranged from 0% (IFN β-1b 250 μg SC every other day, IFN β-1a 30 μg IM once a week) to 43% (IFN β-1a 44 μg SC thrice weekly) and 73% (GA 20 mg SC once daily). However, there were too few studies in each comparison to enable exploration of heterogeneity.Fig. 2Pairwise meta-analyses for annualised relapse rate. IFN: interferon, GA: glatiramer acetate, IM: intramuscular, SC: subcutaneous

Findings derived from the NMA for comparisons between each drug and placebo substantially mirrored those of the pairwise comparisons, and reflected statistically significant reductions in ARR in patients receiving active drugs (see Table [3](#Tab3){ref-type="table"}). There was little evidence of superiority of one drug over another. However, GA 20 mg SC once daily (RR = 0.82, 95% CI \[0.73, 0.93\]), IFN β-1a 44 μg SC thrice weekly (0.85, \[0.76, 0.95\]) and IFN β-1b 250 μg SC every other day (0.86, \[0.76, 0.97\]) all produced significant reductions in ARR as compared to IFN β-1a 30 μg IM once a week. Ranking of the drugs suggested that the drug with the highest cumulative probability of superiority was GA 20 mg SC once daily. We found no evidence of inconsistency.Table 3Network meta-analysis results for annualised relapse rate^a^DrugSUCRAGA 20 mg dailyPegIFN β-1a 125 μg every 2 weeksGA 40 mg thrice weeklyIFN β-1a 44 μg SC thrice weeklyIFN β-1b 250 μg SC every other dayIFN β-1a 22 μg SC thrice weeklyIFN β-1a 30 μg IM weeklyPlaceboGA 20 mg daily0.771.01 (0.77, 1.33)1.00 (0.80, 1.24)0.97 (0.85, 1.10)0.95 (0.86, 1.05)0.91 (0.76, 1.08)0.82 (0.73, 0.92)0.65 (0.59, 0.72)PegIFN β-1a 125 μg every 2 weeks0.730.98 (0.71, 1.35)0.95 (0.72, 1.26)0.94 (0.71, 1.23)0.89 (0.66, 1.21)0.81 (0.62, 1.06)0.64 (0.50, 0.83)GA 40 mg thrice weekly0.700.97 (0.77, 1.22)0.96 (0.77, 1.19)0.91 (0.71, 1.17)0.82 (0.66, 1.03)0.66 (0.54, 0.80)IFN β-1a 44 μg SC thrice weekly0.640.99 (0.86, 1.13)0.94 (0.80, 1.10)0.85 (0.76, 0.95)0.68 (0.60, 0.76)IFN β-1b 250 μg SC every other day0.560.95 (0.79, 1.14)0.86 (0.76, 0.97)0.69 (0.62, 0.76)IFN β-1a 22 μg SC thrice weekly0.430.91 (0.76, 1.08)0.72 (0.61, 0.85)IFN β-1a 30 μg IM weekly0.180.80 (0.72, 0.88)Placebo0Test for inconsistency (χ^2^, df, p)11.71, 11, 0.38^a^Findings are expressed as rate ratio (RR) with 95% CI*IFN* interferon, *GA* glatiramer acetate, *IM* intramuscular, *SC* subcutaneous, *SUCRA* surface under the cumulative ranking curve

Sensitivity analyses {#Sec14}
--------------------

Several characteristics of the trials included in this network suggested that additional analyses would confirm the robustness of our findings. All of these analyses were post hoc. First, after exclusion of the REFORMS 2012 \[[@CR19]\] trial from the analysis (where relapses were self-reported by subjects instead of being documented by an examining neurologist), effect estimates remained essentially unchanged for all pairwise comparisons. Second, we compared findings for studies with 'true', blinded placebos against studies that did not have blinded placebos. That is, several studies did not deliver placebos via the same route of administration \[[@CR14]--[@CR16]\]. We found that effects for these drugs against placebo were robust to inclusion of a covariate in the model for trials without a blinded placebo. Third, after exclusion of the Bornstein 1987 \[[@CR18]\] trial that was an outlier in the comparison between GA 20 mg SC once daily and placebo, the pooled rate ratio for relapses still suggested a reduction in ARR as compared to placebo (RR = 0.71, 95% CI \[0.62, 0.82\]), with I^2^ of 0% (see Additional file [2](#MOESM2){ref-type="media"}). Re-estimation of the NMA yielded a change in the SUCRA-based rankings, with GA 20 mg SC once daily now ranked third, but point estimates and confidence intervals were not substantially different in the new model.

Time to progression confirmed at three months {#Sec15}
---------------------------------------------

Direct evidence from comparisons is shown in Fig. [3](#Fig3){ref-type="fig"}. GA 40 mg thrice weekly was not represented in this analysis. Comparison of drugs against placebo showed a mixed pattern of results. None of the three direct comparisons between active drugs suggested a benefit of one over another. Most comparisons were informed by only one study.Fig. 3Pairwise meta-analyses for time to progression. IFN: interferon, GA: glatiramer acetate, IM: intramuscular, SC: subcutaneous; TTP3: time to progression confirmed at 3 months; TTP6: time to progression confirmed at 6 months

Comparisons for active drugs vs. placebo were similar between the NMA and the pairwise meta-analyses (see Table [4](#Tab4){ref-type="table"}). Notably, additional information from indirect comparisons yielded a more precise estimate of effectiveness for both IFN β-1a 30 μg IM once a week vs placebo (HR = 0.73, 95% CI \[0.53, 1.00\], *p* = 0.0499) and GA 20 mg SC once daily (0.76, \[0.60, 0.97\]). Comparisons between active drugs estimated from the NMA did not indicate that any one drug was statistically better than the others, but ranking of the drugs suggested that the drug with the highest cumulative probability of superiority was IFN β-1a 44 μg SC thrice weekly. We found no evidence of inconsistency.Table 4Network meta-analysis results for time to progression^a^Time to progression confirmed at 3 monthsDrugSUCRAIFN β-1a 44 μg SC thrice weeklyPegIFN β-1a 125 μg every 2 weeksIFN β-1a 22 μg SC thrice weeklyIFN β-1a 30 μg IM weeklyGA 20 mg dailyIFN β-1b 250 μg SC every other dayPlaceboGA 40 mg SC thrice weeklyIFN β-1a 44 μg SC thrice weekly0.771.01 (0.59, 1.74)0.92 (0.65, 1.30)0.86 (0.62, 1.19)0.82 (0.56, 1.22)0.81 (0.53, 1.22)0.63 (0.46, 0.86)Not included in this analysisPegIFN β-1a 125 μg every 2 weeks0.750.91 (0.52, 1.59)0.85 (0.49, 1.46)0.81 (0.49, 1.34)0.80 (0.47, 1.34)0.62 (0.40, 0.97)IFN β-1a 22 μg SC thrice weekly0.620.94 (0.62, 1.42)0.90 (0.59, 1.36)0.88 (0.57, 1.36)0.68 (0.49, 0.96)IFN β-1a 30 μg IM weekly0.50.96 (0.65, 1.42)0.94 (0.62, 1.43)0.73 (0.53, 1.00)\*GA 20 mg daily0.440.98 (0.78, 1.24)0.76 (0.60, 0.97)IFN β-1b 250 μg SC every other day0.390.78 (0.59, 1.02)Placebo0.02Test for inconsistency (χ2, df, p)0.35, 2, 0.84Time to progression confirmed at 6 monthsDrugSUCRAIFN β-1b 250 μg SC every other dayPegIFN β-1a 125 μg every 2 weeksIFN β-1a 44 μg SC thrice weeklyIFN β-1a 30 μg IM weeklyGA 20 mg dailyPlaceboPegIFN β-1a 125 μg every 2 weeksGA 40 mg thrice weeklyIFN β-1b 250 μg SC every other day0.90.74 (0.32, 1.71)0.71 (0.32, 1.60)0.50 (0.29, 0.87)0.42 (0.21, 0.83)0.34 (0.18, 0.63)Not included in this analysisPegIFN β-1a 125 μg every 2 weeks0.710.97 (0.40, 2.33)0.68 (0.35, 1.31)0.56 (0.28, 1.15)0.46 (0.26, 0.81)IFN β-1a 44 μg SC thrice weekly0.70.70 (0.39, 1.25)0.58 (0.27, 1.27)0.47 (0.24, 0.93)IFN β-1a 30 μg IM weekly0.40.83 (0.49, 1.41)0.68 (0.49, 0.94)GA 20 mg daily0.250.82 (0.53, 1.26)Placebo0.05Test for inconsistency (χ2, df, p)0.77, 1, 0.38^a^Findings are presented as HR (95% CI)*IFN* interferon, *GA* glatiramer acetate, *IM* intramuscular, *SC* subcutaneous, *SUCRA* surface under the cumulative ranking curve

Time to progression confirmed at six months {#Sec16}
-------------------------------------------

Direct evidence from comparisons is shown in Fig. [3](#Fig3){ref-type="fig"}. All comparisons drew from a single study, except for IFN β-1a 30 μg IM once a week as compared to placebo. Only three drugs, GA 20 mg SC one daily, IFN β-1a 30 μg SC once weekly and IFN β-1a pegylated 125 μg every 2 weeks, were compared against placebo.

In the NMA, estimates for GA 20 mg SC once daily (HR = 0.82, 95% CI \[0.53, 1.26\]), IFN β-1a 30 μg IM once a week (0.68, \[0.49, 0.94\]) and IFN β-1a pegylated 125 μg every 2 weeks (0.46, \[0.26, 0.81\]) compared to placebo mirrored the direct evidence (see Table [4](#Tab4){ref-type="table"}). Indirect comparisons suggested that both IFN β-1a 44 μg SC thrice weekly (0.47, \[0.24, 0.93\]) and IFN β-1b 250 μg SC every other day (0.34, \[0.18, 0.63\]) showed evidence of delaying disability progression as compared to placebo. The NMA suggested that IFN β-1b 250 μg SC every other day was superior both to IFN β-1a 30 μg IM once a week (HR = 0.50, 95% CI \[0.29, 0.87\]) and to GA 20 mg SC once daily (0.41, \[0.21, 0.83\]), but these findings were driven by the INCOMIN 2002 trial \[[@CR20]\] and relied on a hazard ratio estimated from summary statistics. Ranking of the drugs suggested that the drug with the highest cumulative probability of superiority was IFN β-1b 250 μg SC every other day. Tests of inconsistency in the network did not suggest that direct and indirect evidence were in disagreement; however, the network was sparse and only one comparison included more than one study.

Discontinuation due to AEs {#Sec17}
--------------------------

Two NMA models were estimated: one for studies with 24-month follow-up and one including all studies with the follow-up of greatest maturity. Neither NMA found evidence that one drug was more likely to lead to discontinuation than another. However, confidence intervals were wide and NMA-based estimates were often numerically different to estimates from the direct evidence alone. Moreover, both networks of evidence included some indication of inconsistency. In the 24-month follow-up model, the sidesplitting test suggested that direct and indirect evidence were in conflict for the comparison between GA 20 mg SC once daily and placebo, with indirect evidence suggesting that risk of discontinuation due to AEs was higher than presented in the direct evidence (*p* = 0.037). In the all-studies model, the overall Wald test suggested some signal of inconsistency (*p* = 0.09), though sidesplitting tests did not indicate an obvious source of inconsistency. Full results are in Additional file [2](#MOESM2){ref-type="media"}.

Discussion {#Sec18}
==========

Meta-analyses confirmed that the different formulations of IFN-β and GA reduce ARR and generally delay progression as defined in these trials. There was little evidence that any one drug was superior to others, except for progression confirmed at 6 months, but networks were especially sparse. Findings for discontinuations due to AEs, which are intended to be indicative, did not suggest that one drug was more likely to result in discontinuation than another, but these findings relied on networks with some limited evidence of inconsistency.

Challenges with the clinical evidence {#Sec19}
-------------------------------------

These conclusions are tempered by several considerations. Analyses did not show a clear 'winner' across outcomes, and, again, comparisons between drugs estimated as part of NMA models were in the main inconclusive. Though the main model for ARR was relatively well populated, analyses for time to progression confirmed at six months were especially sparse. In particular, several comparisons of drugs vs. placebo estimated as part of this last model relied exclusively on indirect evidence. Moreover, analyses for time to progression confirmed at three and at six months did not show a consistent pattern, except that all drugs were beneficial in delaying progression where progression was defined using the EDSS. This is particularly concerning, as progression confirmed at six months is considered to be a 'stronger' outcome than progression confirmed at three months.

Measurement of disease progression also relied on the EDSS, a measure that, while broadly accepted in clinical trials, may be of dubious value in measuring disability per se. The EDSS is heavily weighted towards mobility over other important aspects of disability affected by disease progression in MS, such as cognitive function. Additionally, progression outcomes based on confirmed progression at 3 or 6 months overestimate the accumulation of permanent disability by up to 30% \[[@CR21]\]. This is in part because recovery from relapses may take longer than several months, and thus 'confirmed' progression may reflect residual relapse-related symptoms. Consequently, while time to progression confirmed at 3 or 6 months may be standard within the relatively short timeframe of clinical trials, these outcomes may not capture the true accumulation of MS-related disability over the lifecourse, and thus true differences between DMTs in delaying disease progression.

NMA models also had imbalanced risk of bias across the networks of studies. For example, most trials comparing two active treatments were open-label, whereas most trials comparing active treatments against placebos were blinded. Many trials relied on short follow-up, generally less than two years in duration, which increases the risk of spurious results \[[@CR21]\]. Thus, participants were aware of the drugs they were receiving. This might have posed a greater risk for unblinding of outcome assessors than in ostensibly double-blinded trials. In addition, the majority of studies were judged as high risk of bias under the 'other' category of the Cochrane tool given that most of these were funded by drug companies. Although no research has specifically been undertaken in the field of MS trials, empirical examination of trials suggests that industry-sponsored RCTs are more likely to have favourable results than non-industry sponsored RCTs \[[@CR2]\]. A final issue is that patient populations recruited into trials may not be the same over time, given the nearly 20-year span of the trials included in our models. These differences may well extend to diagnostic definitions of MS, and detection and diagnosis of relapses and disease progression. Again, insufficient studies on each pairwise comparison prevented exploration of this problem, but it is conceivable that this might have affected transitivity of our networks of evidence.

Review-level strengths and limitations {#Sec20}
--------------------------------------

We used a rigorous and exhaustive search to locate primary studies, which included updating existing high-quality systematic reviews. Additionally we used auditable and transparent methods to include and synthesise studies. Where appropriate, we undertook post hoc sensitivity analyses in our clinical effectiveness assessments to check the robustness of our findings. However, a limitation of our work, inherent to all systematic reviews, is publication bias. Methods for detecting publication bias in NMAs are still in development, and we did not have enough studies in any one comparison to test for small-study bias. This may be especially relevant since many of the early trials of IFN and GA for MS were small trials. Another important limitation was the selective and inconsistent reporting of outcomes. For example, one of the reasons we did not undertake a meta-analysis of time to first relapse is that there was inconsistent and often poor reporting, especially across multiple reports of the same study, which prevented imputation of hazard ratios. We were also unable to obtain meta-analysable data for one study \[[@CR12]\], due to the tight timeline within which the original work was undertaken.

Our analysis methods had a number of statistical advantages as well as some limitations. In examining the effect of IFN and GA on progression, we used time to event outcomes and hazard ratios instead of calculating risk ratios or odds ratios at different follow-up points. Thus, trial findings were reported at their fullest 'maturity' \[[@CR22]\] and all relevant data were included. We were unable to verify empirically whether hazard ratios and rate ratios were time-varying due to few comparisons on every node of the study networks. On the other hand, we judged that stratifying analyses by time to follow-up would have resulted in excessively sparse networks that would have been difficult to interpret collectively. Thus, our decision to pool study estimates across follow-up times for analyses of clinical outcomes was both a strength and a potential limitation. Notably, we stratified analyses by time to follow-up in NMAs of discontinuations due to AEs, because we judged that the only feasible estimator in these analyses was the risk ratio.

Deviations from protocol {#Sec21}
------------------------

In our protocol, we specified that the comparator of interest was best supportive care without DMTs. In practice, this includes both best supportive care and also placebo, as reported in included trials. Though we sought to examine 10 outcomes relevant to RRMS in our original protocol, we report here findings for relapse rate, disability and discontinuation due to adverse events, as synthesis for other outcomes was limited and in many parts meta-analysable. Detailed findings for each of these outcomes are available in the main report \[[@CR2]\]. Moreover, disability was ultimately measured and included in these meta-analyses as 'time to progression', as this was the most common outcome across trials. Finally, we implemented network meta-analyses in a frequentist paradigm rather than using WinBUGS as specified in the protocol.

In relation to research and practice {#Sec22}
------------------------------------

Our findings updated prior reviews, though comparability of findings is limited. We included trials examining IFN and GA against each other and against a no-treatment comparator, and restricted inclusion to doses and formulations within their marketing authorisation as compared to Tramacere et al. \[[@CR3]\] who broadly examined immunomodulators and immunosuppressants for RRMS. Because they included studies across drugs and because they used risk ratios as the sole outcome estimator, our analyses and theirs are largely incommensurate. Our systematic review and NMA may however offer more clinically relevant evidence because of our focus on doses used in clinical practice. However, our analyses for discontinuation due to AEs agreed with theirs. Neither review suggested that any one drug had a significant effect on discontinuation due to AEs relative to placebo.

Our findings agree with the ABN guidelines \[[@CR1]\] in that the guidelines classify IFN-β and GA as drugs of 'moderate efficacy', and observe that there is not much data to support differences in effectiveness between them. Our analysis does suggest that these drugs are effective in reducing relapse rate, which may have an effect on progression.

Longer-term observational cohorts have also examined DMT effectiveness over time and shed some doubt on the findings from randomised trials. In the year 8 analyses from the UK Risk Sharing Scheme, DMTs were not found to be cost-effective and the drugs assessed were not substantially different in terms of delays in disease progression (personal communication with UK Department of Health, 2016). An analysis from the MSBase study, an international registry with 'real-world' data from MS patients, has suggested that GA or subcutaneous IFN-β-1a are more effective in controlling relapse rate than other IFN-β, though drugs were not different on disease progression \[[@CR23]\]. While this analysis relied on matching to overcome lack of randomisation, a strength is that it used disability progression confirmed at 12 months instead of at 3 or 6 months.

Future research {#Sec23}
---------------

First, findings from this review will require updating as generic versions of the DMTs considered here are authorised. For example, the GATE trial also tested a generic version of glatiramer acetate against the branded version and placebo \[[@CR24]\]. Key flaws in the assembled clinical effectiveness evidence included the lack of long-term follow-up and the absence of a measure for disease progression adequately capturing worsening of disability. A large-scale, longitudinal randomised trial comparing active first-line agents and using clinically meaningful and robust measures of disability progression would contribute towards resolving uncertainty about the relative benefits of different IFN or GA formulations (and other first line agents). While other, newer first line agents were beyond the remit of our systematic review, few randomised comparisons exist and thus a large trial could resolve remaining questions of comparative effectiveness. It may also be that using standardised definitions for relapses and disease progression together with blinded adjudicator panels could attenuate the risk of bias accruing to an open-label trial. Because of this lack of long-term follow-up, DMT trials are not informative on whether drugs delay progression to SPMS. Understanding long-term effectiveness of DMTs as described above would will also provide better information for informing cost-effectiveness evaluations, the effectiveness estimates for which currently rely on extrapolation from short-term trials. Use of a more relevant measure for disability and disease progression, especially as regards the development of secondary progressive MS, will also lead to better and more robust valuation of benefits accruing from DMTs.

Finally, above and beyond the broad interpretation that DMTs reduce ARR, there is a need to understand who responds best to DMTs; especially who does not respond to IFN or GA early on, to enable more targeted therapeutic decisions. Though several trials included in our clinical effectiveness review used subgroup analyses, based for example, on presenting lesions or demographic characteristics, a more fine-grained understanding can help patients and clinicians make better-informed decisions.

Conclusions {#Sec24}
===========

Our meta-analyses confirmed that IFN-β and GA reduce ARR and generally delay progression as defined in these trials. We found, however, that there was no clear 'winner' across outcomes, and our findings were qualified by the high risk of bias across studies, and the use of an impairment/mobility scale to measure disease progression. Future research should consider more relevant measures of disability and, given that most trials have been short-term, consider a longitudinal approach to comparative effectiveness.
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Additional file 1:Detailed search and data preparation methods. This file includes search strings, grey literature search sources, a sample data extraction form, and additional details on the statistical procedures undertaken to prepare study data for meta-analysis. (DOCX 47 kb) Additional file 2:Additional results. This file includes detailed reasons for exclusion, tables of included publications, and sensitivity analyses for ARR, and detailed findings for discontinuation due to adverse events. (DOCX 265 kb)
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